Ractigen Therapeutics Achieves FDA IND Clearance for Revolutionary saRNA Treatment of Proliferative Vitreoretinopathy#United_States#Ractigen_Therapeutics#Nantong#RAG-1C#saRNA_therapy
Ractigen Therapeutics Achieves FDA IND Clearance for Revolutionary saRNA Treatment of Proliferative Vitreoretinopathy
Ractigen Therapeutics announces groundbreaking FDA IND clearance for RAG-1C, a first-of-its-kind saRNA therapy targeting Proliferative Vitreoretinopathy, offering new hope in ocular treatment.
third-news.com
July 31, 2026 at 11:08 AM
Ractigen Therapeutics Achieves FDA IND Clearance for Revolutionary saRNA Treatment of Proliferative Vitreoretinopathy#United_States#Ractigen_Therapeutics#Nantong#RAG-1C#saRNA_therapy